1Master Student, Department of Pharmacology and Toxicology, Tishreen University, Latakia, Syria
2Professor, Department of Pharmacology and Toxicology, Tishreen University, Latakia, Syria
*Corresponding Author E-mail: samikherro123@gmail.com
**rana.makhous@tishreen.edu.sy
Online published on 13 June, 2022.
The aim of this study was to evaluate the effect of simvastatin on the bone remolding markers in rats (experimental study).
The study involved 18 male Wistar rats, they were divided into three groups: Group I (n=6; control group), Group II (n=6; was administrated 7.5 mg/kg/dexamethasone intra muscular for 2 months served as a model of osteoporosis [op]), Group III (n=6;was administered 7.5 mg/kg/dexamethasone intra muscular for 2month and treated orally with 8mg/kg of simvastatin).After 8 weeks, serum acid phosphatase was determined for the three group.
The levels of serum acid phosphatase were notably elevated in the [op] group. Administration of simvastatin produced a significant decrease in the levels of serum acid phosphatase.
Simvastatin was able to decrease the rate of bone resorption in an animal model of osteoporosis induced by dexamethasone.
Statins, Simvastatin, Osteoporosis, ACP, Bone resorption
